Less Ads, More Data, More Tools Register for FREE

Second vaccine clears path out of pandemic by spring - UK's Hancock

Wed, 30th Dec 2020 07:11

LONDON, Dec 30 (Reuters) - The Oxford University-AstraZeneca
COVID-19 vaccine approved by Britain on Wednesday provides a
path out of the pandemic by the spring, by which time millions
of vulnerable people will be protected, Health Secretary Matt
Hancock said.

He said the recommended 12-week gap between the first and
second doses of the Oxford-AstraZeneca shot was "very helpful"
because it enabled more people to be immunized with a first shot
that offered a high level of protection on its own.

(Reporting by Paul Sandle; editing by Guy Faulconbridge)

Related Shares

More News
Today 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

Today 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

Today 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III t...

Today 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or ...

12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.